Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.9052W HIGH $10.21
Volume
256.14 K
Value Traded
117.68 M
Short % Float
16.53%
-10.28%Week
+7.64%1 Month
+0.63%3 Month
+95.38%6 Month
-57.59%5 Year
-56%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.19 B
EPS (TTM)
-0.28
P/E Ratio
-
Ent. Value
2.01 B
Total Shares
266.29 M
Float Shares
216.14 M
Insiders
20.33%
Institutions
64.10%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
BFLY Catalyst Timeline
Dated clinical, regulatory and corporate events for Butterfly Network, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Butterfly Network, Inc.
2Total events
0Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Past FDA Catalysts and PDUFA Decisions
How BFLY actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Butterfly Network, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every BFLY program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| DEVIVO JOSEPHDirector, Officer (President & CEO) | Sell | -35,790 7,311,930 held | $10.02 | 10/06/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BFLY
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PARKMAN HEALTHCARE PARTNERS LLC | 0.2 % | 2.20 M | 544.48 K | 439.97% ( 443.64 K) |
BFLY Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BFLY ranks across every disease it competes in
Competitive Position is a premium feature
See how BFLY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBFLY News
BFLY▲ +2.6%today
Butterfly Network to Report Third Quarter 2026 Financial Results on October 29, 2026
Butterfly Network, Inc. will announce its financial results for the third quarter of 2026 on October 29, 2026. The report will be presented by CEO Joseph DeVivo and CFO John Doherty during a conference call and webcast. This event highlights the company's ongoing commitment to transparency and investor engagement.
Read more →BFLY▲ +2.6%today
Bridge Neurotech and Butterfly Network Announce Partnership to Develop Fully Non-Invasive Brain-Computer Interface
Bridge Neurotech and Butterfly Network have formed a partnership to develop a fully non-invasive brain-computer interface. This collaboration combines Bridge's innovative approach with Butterfly's expertise in ultrasound technology and AI. The partnership aims to advance the field of BCIs, making them more accessible and effective for users.
Read more →BFLYButterfly Network Appoints Mike Noonen to Board of Directors
Butterfly Network has appointed Mike Noonen to its Board of Directors, effective October 9, 2026. Noonen, a seasoned semiconductor executive, will serve on the Compensation and Technology Committees. His addition expands the Board to seven members, enhancing the company's leadership in semiconductor-based ultrasound technology.
Read more →BFLYMendaera’s Focalist™ System Now Compatible with Butterfly’s Ultrasound-on-Chip™ Technology
Mendaera, Inc. has announced that its Focalist™ system is now compatible with Butterfly Network's Ultrasound-on-Chip™ technology. This integration aims to enhance procedural medicine by combining Mendaera's handheld system with Butterfly's advanced imaging capabilities. The Focalist system is already FDA-cleared, indicating its readiness for commercial use.
Read more →BFLYButterfly Network to Participate in Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026
Butterfly Network, Inc. will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026. Key executives, including CEO Joseph DeVivo and CFO John Doherty, will represent the company. This participation highlights Butterfly's role in the healthcare industry, particularly in ultrasound technology.
Read more →BFLYMerge Labs and Butterfly Network Partner to Advance Ultrasound-Based Brain-Computer Interfaces
Butterfly Network, Inc. and Merge Labs have entered a multi-year licensing agreement. This partnership allows Merge to utilize Butterfly's advanced Poseidon Family of Ultrasound-on-Chip technology. The focus will be on developing ultrasound-based brain-computer interfaces, showcasing a commitment to innovation in healthcare technology.
Read more →BFLYButterfly Network Congratulates Dr. Erica Schwartz on Confirmation as CDC Director
Butterfly Network, Inc. has congratulated Dr. Erica Schwartz on her confirmation as the new director of the CDC. Dr. Schwartz, who has been a member of Butterfly's Board of Directors since 2021, will step down from her position on the board effective August 5, 2026, prior to her new role. This marks a significant leadership change for both the CDC and Butterfly Network.
Read more →BFLY▲ +15.1%on this news
Butterfly Network Reports Second Quarter 2026 Financial Results
Butterfly Network, Inc. reported its financial results for the second quarter of 2026, showcasing performance that surpassed their guidance expectations. The company, known for its innovative ultrasound devices and AI software, continues to demonstrate strong growth and leadership in the medical technology sector. CEO Joseph DeVivo highlighted the company's achievements in this quarter.
Read more →BFLYScience Corp. Names Nevada Sanchez as Executive Vice President of Engineering
Science Corporation has appointed Nevada Sanchez as Executive Vice President of Engineering. Sanchez, who co-founded Butterfly Network, Inc., will lead engineering efforts and report to CEO Max Hodak. This strategic move aims to bolster the company's capabilities in neural engineering and brain-computer interface technology.
Read more →BFLYButterfly Network to Report Second Quarter 2026 Financial Results on July 30, 2026
Butterfly Network, Inc. has announced that it will report its financial results for the second quarter of 2026 on July 30, 2026. The report will be followed by a conference call and webcast hosted by key executives, including the CEO and CFO. This event is anticipated to provide insights into the company's performance and future outlook.
Read more →BFLYButterfly Network Expands its Handheld Ultrasound Availability into Brazil
Butterfly Network has announced the expansion of its handheld ultrasound devices into Brazil. This move aims to enhance access to advanced medical imaging technology in the region. The initiative is expected to significantly improve healthcare delivery and patient outcomes in Brazil.
Read more →BFLY▲ +10.8%on this news
Butterfly Network’s Embedded™ Partner Aleph Neuro Unveils Stunning Brain Images
Butterfly Network's partner, Aleph Neuro, has introduced impressive brain imaging technology. This development highlights advancements in neuroimaging capabilities. The article emphasizes the significance of these images in understanding brain health and potential applications in medical diagnostics.
Read more →BFLY▲ +55.9%on this news
Butterfly Network Provides Commentary on Midjourney Medical’s Full Body Ultrasound Scanner Announcement
Butterfly Network has commented on the announcement made by Midjourney Medical regarding their full body ultrasound scanner. The details of this commentary are not specified in the provided text. The context suggests a focus on advancements in ultrasound technology, but further information is needed for a comprehensive understanding.
Read more →BFLY▲ +5.4%on this news
Butterfly Network to Participate in TD Cowen’s Medical Devices Emerging Growth Call Series on June 18, 2026
Butterfly Network is set to participate in TD Cowen's Medical Devices Emerging Growth Call Series on June 18, 2026. This event will provide an opportunity for the company to discuss its innovations and growth prospects in the medical devices sector. Further details about the event and participation specifics have not been disclosed.
Read more →BFLYButterfly Network to Participate in the William Blair 46th Annual Growth Stock Conference
Butterfly Network is set to participate in the William Blair 46th Annual Growth Stock Conference. This event is an opportunity for the company to showcase its innovations and engage with investors. Further details about their presentation or agenda have not been disclosed.
Read more →BFLYButterfly Network Appoints Caroll H. Neubauer to Board of Directors
Butterfly Network has appointed Caroll H. Neubauer to its Board of Directors. This strategic move is aimed at enhancing the company's leadership and governance. Neubauer brings extensive experience in the healthcare industry, which could benefit Butterfly Network's future initiatives.
Read more →BFLY▼ -6.8%on this newsshared move
Butterfly Network to Present at the Bank of America Securities 2026 Global Healthcare Conference
Butterfly Network, Inc. will present at the Bank of America Securities 2026 Global Healthcare Conference on May 12, 2026. CEO Joseph DeVivo and CFO John Doherty will lead the presentation and host investor meetings. The event highlights Butterfly's advancements in ultrasound technology and its commitment to accessible healthcare solutions.
Read more →BFLYButterfly Network Reports First Quarter 2026 Financial Results
Butterfly Network, Inc. reported strong financial results for Q1 2026, achieving a 25% revenue growth year-over-year. The company highlighted improvements in gross margins and successful product rollouts, including an FDA-cleared AI tool. Despite a net loss, Butterfly remains focused on expanding its market presence and enhancing its technology platform.
Read more →BFLYButterfly Network Appoints Arun Nagdev, MD as Chief Medical Officer – POCUS
Butterfly Network has appointed Arun Nagdev, MD, as Chief Medical Officer for its Point-of-Care Ultrasound (POCUS) division. Dr. Nagdev will be responsible for leading the global medical strategy, which includes advancing clinical product validation and enhancing customer engagement. This strategic move aims to bolster the company's position in the POCUS market.
Read more →BFLY▲ +8.8%on this newsshared move
Butterfly Network to Report First Quarter 2026 Financial Results on April 30, 2026
Butterfly Network has announced that it will report its financial results for the first quarter of 2026 on April 30, 2026. This announcement is part of the company's regular financial reporting schedule. Further details regarding the results will be provided at that time.
Read more →About Butterfly Network, Inc.
Headquarters1600 DISTRICT AVENUE, BURLINGTON, MA, 01803
Founded2011
BIOPHARMAWATCH ELITE PLUS
Trade the next BFLY catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime